Description
BI-1823911 is an experimental drug being studied by Boehringer Ingelheim. It is currently in Phase 1 clinical trials for various advanced cancers, including colorectal cancer. These trials are primarily focused on determining the safe dosage of the drug, both when given alone and in combination with another investigational drug called BI-1701963. The trials specifically include patients whose tumors have a KRAS mutation (specifically the G12C type), which is a common change in colorectal cancer that can help tumors grow. The goal is to see if BI-1823911 can be tolerated and potentially shrink tumors in patients with KRAS-mutated advanced cancers who have not responded well to previous treatments or have limited treatment options. It is taken as a daily tablet.
Mechanism of Action
BI-1823911 is being investigated as a potential treatment for cancers with KRAS mutations. KRAS mutations are changes in a gene that can lead to uncontrolled cell growth. BI-1823911 is designed to target the KRAS protein, potentially interfering with its function in a way that may slow or stop tumor growth. The specific way BI-1823911 interacts with the KRAS protein is being studied in clinical trials.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.